ScreenerHero

XBIO Xenetic Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · xeneticbio.com
2.210USD+4.25%Mkt Cap: 5.18M $P/E: —

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.18M USD
Enterprise Value-1.50M USD
Revenue (TTM)3.26M USD
Gross Profit3.26M USD
Net Income (TTM)-2.68M USD
Revenue/Share1.57 USD
Last Price2.210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.21
PEG—
EV/EBITDA—
EV/Revenue-0.46
P/S1.52
P/B0.82
EPS (TTM)-1.12
EPS (Forward)-0.66
52W Range
1.8703% of range13.93
52W High13.93 USD
52W Low1.870 USD
Profitability
Gross Margin100.00%
Oper. Margin-147.09%
EBITDA Margin0.00%
Profit Margin-90.07%
ROE-36.25%
ROA-32.05%
Growth
Revenue Growth12.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.29M USD
CapEx (TTM)—
FCF Margin-36.03%
FCF Yield-22.69%
Net Debt-6.47M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.43
Quick Ratio7.23
Book Value/Sh2.59 USD
Cash/Share2.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 25, 2019
Splits
Last Split1:10
Split DateMay 15, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.34M
Float1.89M
Insiders11.43%
Institutions6.49%
Short Interest
Short Ratio0.6d
Short % Float1.00%
Short % Out.0.96%
Shares Short22.46K
Short (prev mo.)45.17K
Technical
SMA 503.209 (-31.1%)
SMA 2002.856 (-22.6%)
Beta2.20
S&P 52W Chg16.45%
Avg Vol (30d)106.22K
Avg Vol (10d)50.11K
Technical Indicators
RSI (14)32.2
MACD-0.3718
MACD Signal-0.2754
MACD Hist.-0.0965
BB Upper4.911 USD
BB Middle3.019 USD
BB Lower1.127 USD
BB Width125.36%
ATR (14)0.3451 USD
Vol Ratio (20d)0.11x